Table 2.
Change in patient characteristics during the study period.
| Negative BeAM value |
High BeAM value |
|||||
|---|---|---|---|---|---|---|
| Baseline (mean ± SD) | Endpoint (mean ± SD) | p-value | Baseline (mean ± SD) | Endpoint (mean ± SD) | p-value | |
| Weight (kg) | 93.1 (16.1) | 92.3 (14.6) | 0.2501 | 87.7 (17.0) | 88.6 (17.1) | <0.0001 |
| BMI (kg/m2) | 32.8 (5.1) | 32.6 (4.7) | 0.2948 | 30.7 (5.1) | 31.1 (5.1) | <0.0001 |
| HbA1c level (%) | 7.2 (0.9) | 7.2 (1.1) | 0.9324 | 7.5 (0.7) | 7.2 (0.8) | <0.0001 |
| FBG (mg/dl) | 114.9 (13.8) | 131.3 (32.7) | 0.0224 | 105.6 (16.0) | 114.3 (25.6) | <0.0001 |
| PPG (mg/dl) | 157.0 (28.8) | 144.1 (43.1) | 0.1367 | 201.8 (47.9) | 143.1 (40.6) | <0.0001 |
| Insulin glargine dose (units) | 33.0 (30.9) | 43.1 (32.8) | <0.0001 | 37.8 (25.8) | 44.7 (31.8) | <0.0001 |
| Insulin glulisine dose (units) | 4.0 (1.6) | 12.5 (7.5) | <0.0001 | 5.1 (1.8) | 12.3 (6.7) | <0.0001 |
Negative BeAM value is <0 mg/dl; high BeAM value is >50 mg/dl. BMI, body mass index; HbA1c, glycated haemoglobin; FBG, fasting blood glucose; PPG, postprandial glucose; SD, standard deviation.